Last reviewed 2026-05-31 · How we verify

Prevascar

Renovo · Phase 2 active Small molecule ✓ Verified May 2026

Prevascar is a Small molecule drug developed by Renovo. It is currently in Phase 2 development. Also known as: IL-10, Ilodecakin, RN1003.

Prevascar is a protein-based intervention that has been studied for its potential to reduce scarring and improve wound healing. It is a non-glycosylated form of interleukin-10, which has been investigated in a clinical trial (NCT00984646) for its efficacy in reducing cicatrix.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Prevascar
Also known as	IL-10, Ilodecakin, RN1003
Sponsor	Renovo
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Prevascar CI brief — competitive landscape report
Prevascar updates RSS · CI watch RSS
Renovo portfolio CI

Frequently asked questions about Prevascar

What is Prevascar?

Prevascar is a Small molecule drug developed by Renovo.

Who makes Prevascar?

Prevascar is developed by Renovo (see full Renovo pipeline at /company/renovo).

Is Prevascar also known as anything else?

Prevascar is also known as IL-10, Ilodecakin, RN1003.

What development phase is Prevascar in?

Prevascar is in Phase 2.

Manufacturer: Renovo — full pipeline
Therapeutic area: All drugs in Other
Also known as: IL-10, Ilodecakin, RN1003

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing